Chronic nonsteroidal anti-inflammatory drug (NSAID) use suppresses multiple CpG islands hyper methylation (CIHM) of tumor suppressor genes in the human gastric mucosa

Cancer Science

Volumn 100, Issue 7, 2009, Pages 1192-1197

  Tahara, Tomomitsu ^a   Shibata, Tomoyuki ^a   Yamashita, Hiromi ^a   Nakamura, Masakatsu ^a   Yoshioka, Daisuke ^a   Okubo, Masaaki ^a   Hirata, Ichiro ^a   Arisawa, Tomiyasu ^b  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEATH ASSOCIATED PROTEIN KINASE; DICLOFENAC; ETODOLAC; LORNOXICAM; LOXOPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; UVOMORULIN;

ADULT; AGE; AGED; ARTHRALGIA; ARTICLE; BRAIN DISEASE; CANCER INHIBITION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CPG ISLAND; CPG ISLAND HYPER METHYLATION; DEATH ASSOCIATED PROTIN KINASE GENE; DNA METHYLATION; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; E CADHERIN GENE; FEMALE; GENE; GENE REPRESSION; HELICOBACTER INFECTION; HUMAN; HUMAN TISSUE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MYALGIA; P14 (ARF) GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH MUCOSA; TREATMENT DURATION; TUMOR SUPPRESSOR GENE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CPG ISLANDS; DNA METHYLATION; FEMALE; GASTRIC MUCOSA; GASTROINTESTINAL NEOPLASMS; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MIDDLE AGED;

EID: 67449116215     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01175.x     Document Type: Article

References (51)

1. Hawkey CJ. Non-steroidal anti-inflammatory drug gastropathy. Gastroenterology 2000; 119: 521-35.
2. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russel RI. Gastrointestinal damage associated with the use of non-steroidal anti-inflammatory drugs. N Eng J Med 1992; 327: 749-54.
3. Wolf MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. N Eng J Med 1999; 340: 1888-999.
4. Rich M, Scheiman JM. Nonsteroidal anti-inflammatory drug gastropathy at the millennium: Mechanisms and prevention. Semin Arthritis Rheum 2000; 30: 167-79.
5. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252-66.
6. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48: 4399-404.
7. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991; 83: 355-8.
8. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-6.
9. Giovannucci E, Egan KM, Hunter DJ et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333: 609-14.
10. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: Case control study in general practice research database. BMJ 2000; 320: 1642-6.
11. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993; 15 (53): 1322-7.
12. Coogan PF, Rosenberg L, Palmer JR et al. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev 2000; 1: 119-23.
13. Farrow DC, Vaughan TL, Hansten PD et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998; 2: 97-102.
14. Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995; 76: 1116-19.
15. Yang HB, Cheng HC, Sheu BS, Hung KH, Liou MF, Wu JJ. Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication. Aliment Pharmacol Ther 2007; 15 (25): 455-61.
16. Toyota M, Ahuja N, Suzuki H et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999; 59: 5438-42.
17. Kang GH, Shim YH, Jung HY, Kim WH, Ro JY, Rhyu MG. CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res 2001; 61: 2847-51.
18. Chan AO, Lam SK, Wong BC et al. Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer. Gut 2003; 52: 502-6.
19. Waki T, Tamura G, Sato M, Terashima M, Nishizuka S, Motoyama T. Promoter methylation status of DAP-kinase and RUNX3 genes in neoplastic and non-neoplastic gastric epithelia. Cancer Sci 2003; 94: 360-4.
20. Kang GH, Lee HJ, Hwang KS, Lee S, Kim JH, Kim JS. Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am J Pathol 2003; 163: 1551-6.
21. Maekita T, Nakazawa K, Mihara M et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 2006; 12: 989-95.
22. Tahara T, Arisawa T, Shibata T et al. Increased number of methylated CpG islands correlates with Helicobacter pylori infection, histological and serological severity of chronic gastritis. Eur J Gastroenterol Hepatol 2009 (e-pub ahead of print).
23. Tahara T, Arisawa T, Shibata T et al. Risk prediction of gastric cancer by analysis of aberrant DNA methylation in non-neoplastic gastric epithelium. Digestion 2007; 75: 54-61.
24. Kaise M, Yamasaki T, Yonezawa J, Miwa J, Ohta Y, Tajiri H. CpG island hypermethylation of tumor-suppressor genes in H. pylori-infected non-neoplastic gastric mucosa is linked with gastric cancer risk. Helicobacter 2008; 13: 35-41.
25. Nakajima T, Maekita T, Oda I et al. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol Biomarkers Prev 2006; 15: 2317-21.
26. Tahara T, Shibata T, Nakamura M et al. Chronic aspirin use suppresses CDH1 methylation in human gastric mucosa. Dig Dis Sci (e-pub ahead of print).
27. Tahara T, Shibata T, Nakamura M et al. MTHFR 677 T carrier influences the methylation status of H. pylori infected gastric mucosa in older subjects. Dig Dis Sci 2008 (e-pub ahead of print).
28. Sipponen P, Kekki M, Haapakoski J, Ihamaki T, Siurala M. Gastric cancer risk in chronic gastritis: Statistical calculations of cross-sectional data. Int J Cancer 1985; 35: 173-7.
29. Enomoto H, Watanabe H, Nishikura K, Umezawa H, Asakura H. Topographic distribution of Helicobacter pylori in the resected stomach. Eur J Gastroenterol Hepatol 1998; 10: 473-8.
30. Esteller M, Tortola S, Toyota M et al. Hypermethylation-associated inactivation of p14 (ARF) is independent of p16 (INK4a) methylation and p53 mutational status. Cancer Res 2000; 60: 129-33.
31. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996; 93: 9821-6.
32. Katzenellenbogen RA, Baylin SB, Herman JG. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 93: 4347-53.
33. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen rececptor CpG island links ageing and neoplasma in human colon. Nature Genet 1994; 7: 536-40.
34. Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 1998; 8: 5489-94.
35. Issa JP. Aging, DNA methylation and cancer. Crit Rev Oncol Hematol 1999; 32: 31-43.
36. Kondo Y, Issa JP. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev 2004; 23: 9-39.
37. Issa PJ, Ahuja N, Toyota M, Bronner P, Brentnall TA. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 2001; 61: 3573-7.
38. Pereira MA, Tao L, Wang W et al. Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-alpha gene in rat colon tumors. Carcinogenesis 2004;25: 1917-23.
39. Velicescu M, Weisenberger DJ, Gonzales FA, Tsai YC, Nguyen CT, Jones PA. Cell division is required for de novo methylation of CpG islands in bladder cancer cells. Cancer Res 2002; 62: 2378-84.
40. Song JZ, Stirzaker C, Harrison J, Melki JR, Clark SJ. Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells. Oncogene 2002; 21: 1048-61.
41. De Smet C, Loriot A, Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells. Mol Cell Biol 2004; 24: 4781-90.
42. Ushijima T, Okochi-Takada E. Aberrant methylations in cancer cells: where do they come from? Cancer Sci 2005;96: 206-11.
43. Zhu GH, Yang XL, Lai KC et al. Nonsteroidal antiinflammatory drugs could reverse Helicobacter pylori-induced apoptosis and proliferation in gastric epithelial cells. Dig Dis Sci 1998; 43: 1957-63.
44. Hudson N, Balsitis M, Filipowicz F, Hawkey CJ. Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993; 34: 748-51.
45. Ristimäki A, Honkanen N, JänkäläH, Sipponen P, Härkönen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57: 1276-80.
46. Uefuji K, Ichikura T, Mochizuki H, Shinomiya N. Expression of cyclooxygenase-2 protein in gastric adenocarcinoma. J Surg Oncol 1998;69: 168-72.
47. Sung JJ, Leung WK, Go MY et al. Cyclooxygenase-2 expression in Helicobactor pylori associated premalignant and malignant gastric lesions. Am J Pathol 2000; 157: 729-35.
48. Hu PJ, Yu J, Zeng ZR et al. Chemoprevention of gastric cancer by celecoxib in rats. Gut 2004; 53: 195-200.
49. Karin M, Cao Y, Greten FR, Li ZW. NF-kappa B in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301-10.
50. Lin A, Karin M. NF-kappa B in cancer: A marked target. Semin Cancer Biol 2003; 13: 107-14.
51. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I (kappa) B kinase-beta. Nature 1998; 396: 77-80.